Filing Flows › Fusemachines (FUSE) › Guidance & outlook

Fusemachines (FUSE) guidance and outlook

Fusemachines' 10-Q filed Nov 3, 2026 makes 23 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 3, 2026

• Group PRM was issued shares of Common Stock pursuant to the Vendor SPA in consideration for its unpaid consulting fees, and the Company expects to settle the action brought by Mr.
• The Company intends to actively monitor the bid price for its common stock and evaluate available options to regain compliance within the compliance period.
• Although the Company is considering all available options to regain compliance with the MVLS Requirement, there can be no assurance that the Company will be able to do so.
• Although we entered into the Purchase Agreement during 2026, we expect that additional capital will be required to fund operations, support product development, expand selling and marketing activities, and meet our working capital requirements.
• However, there can be no assurance that sufficient funding will be available to us to fund our operating expenses and to further develop our business.
• Unless we achieve substantial profitability, we anticipate that we will likely need to raise additional capital to fund our operations while we implement and execute our business plan.
• As part of our sales efforts, we also provide our platforms to potential customers at no or low cost initially to them for evaluation purposes through short-term pilot deployments of our platforms, and there is no guarantee that we will be able to convert customers from these short-term pilot deployments to full revenue generating contracts.
• We will qualify as a smaller reporting company for so long as either (i) the market value of our common stock held by non-affiliates is less than $250 million, measured on the last business day of our most recently completed second fiscal quarter, or (ii) our annual revenues are less than $100 million during our most recently completed fiscal year and the market value of our common stock held by non-affiliates is…
• Provision for income tax – Provision for income tax is accounted for using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our unaudited condensed consolidated interim financial statements or tax returns.
• Further, we utilize these measures, in addition to GAAP measures, when evaluating and comparing our operating performance against internal financial forecasts and budgets.
• Because the $4.20 conversion price of these notes substantially exceeds the trading price of our common stock as of the date of filing of this report, we expect to be required to repay these notes in cash at maturity unless they are refinanced or restructured, and there can be no assurance that we will be able to do so.
• Management currently expects that the Company will be able to access additional sources of capital, including through issuances of equity securities (such as under the Purchase Agreement) and/or additional borrowings, as and when required to fund the Company’s operating and investing activities over the next year; however, there can be no assurance that such financing will be available on acceptable terms or at all.

Fusemachines' latest quarter

Questions

What does Fusemachines expect?

Group PRM was issued shares of Common Stock pursuant to the Vendor SPA in consideration for its unpaid consulting fees, and the Company expects to settle the action brought by Mr. The Company intends to actively monitor the bid price for its common stock and evaluate available options to regain compliance within the compliance period. Although the Company is considering all available options to regain compliance with the MVLS Requirement, there can be no assurance that the Company will be able to do so.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.